These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 949459)

  • 21. Adjuvant therapy for malignant melanoma.
    Kaiser LR; Burk MW; Morton DL
    Surg Clin North Am; 1981 Dec; 61(6):1249-57. PubMed ID: 7313933
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proceedings: Treatment of a metastasizing murine tumour with Corynebacterium parvum.
    Sadler TE; Castro JE
    Br J Cancer; 1975 Feb; 31(2):264. PubMed ID: 1164486
    [No Abstract]   [Full Text] [Related]  

  • 24. Protection by Corynebacterium parvum against tumour cells injected intravenously.
    Milas L; Mujagić H
    Rev Eur Etud Clin Biol; 1972 May; 17(5):498-500. PubMed ID: 4648182
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of glucan and other adjuvants on the clearance of radiolabeled tumor cells from mouse lungs.
    Proctor JW; Stiteler RD; Yamamura Y; Mansell PW; Winters R
    Cancer Treat Rep; 1978 Nov; 62(11):1873-80. PubMed ID: 728905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM; Oettgen HF
    Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract]   [Full Text] [Related]  

  • 29. Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.
    Scott MT
    J Natl Cancer Inst; 1976 Mar; 56(3):675-7. PubMed ID: 815560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of BCG and other bacteria against neoplasia in mice and hamsters.
    Lemonde P
    Natl Cancer Inst Monogr; 1973 Dec; 39():21-32. PubMed ID: 4362522
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects and mode of action of Corynebacterium parvum on murine tumour metastases.
    Castro JE; Sadler TE; Jones PD
    Dev Biol Stand; 1977 Apr 13-15; 38():277-81. PubMed ID: 608510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organ distribution of technetium-99m-labeled corynebacterium parvum in normal and tumor-bearing mice.
    Barth RF; Singla O
    Cancer Res; 1978 Jan; 38(1):32-4. PubMed ID: 618580
    [No Abstract]   [Full Text] [Related]  

  • 33. The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases.
    Sadler TE; Castro JE
    Br J Surg; 1976 Apr; 63(4):292-6. PubMed ID: 1276661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice.
    Wolmark N; Levine M; Fisher B
    J Reticuloendothel Soc; 1974 Oct; 16(4):252-7. PubMed ID: 4455907
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
    Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J
    Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined use of local irradiation and Corynebacterium parvum in the treatment of the murine line 1 lung carcinoma.
    Ullrich RL; Adams LM
    Radiat Res; 1978 Feb; 73(2):267-73. PubMed ID: 204955
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 38. Failure of preoperative C. parvum vaccine to modify secondary disease following excision of two non-immunogenic murine carcinomas.
    Hewitt HB; Blake ER
    Br J Cancer; 1978 Aug; 38(2):219-23. PubMed ID: 698036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calmette-Guerin bacillus treatment of experimental conjunctival malignant melanoma.
    Rutgard J; Peyman GA; Frenkel M; Saks S
    Arch Ophthalmol; 1977 Dec; 95(12):2214-7. PubMed ID: 588117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):855-60. PubMed ID: 4213015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.